Lord, Abbett & Co
SIOX

Lord, Abbett & Co’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Lord, Abbett & Co’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,625
Closed -$310K – 926
2017
Q3 		$310K Buy
5,625
+1,875
+50% +$316K ﹤0.01% 854
2017
Q2 		$696K Buy
+3,750
New +$657K ﹤0.01% 868

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Lord, Abbett & Co's SIOX Position: Q4 2017 in Review

Lord, Abbett & Co sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 5,625 shares — an estimated $310K sold.

Lord, Abbett & Co first reported a position in SIOX in Q2 2017 and held it in 2 quarters. The position peaked at $696K in Q2 2017. 104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • Lord, Abbett & Co reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Lord, Abbett & Co sold 5,625 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $310K.
  • Lord, Abbett & Co first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2017 and held it in 2 quarters.
  • Lord, Abbett & Co's Sio Gene Therapies Inc. Common Stock position peaked at $696K in Q2 2017.
  • 104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on Lord, Abbett & Co's 13F filing for Q4 2017, filed 14 Feb 2018.